[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629173":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":17,"armGroups":27,"interventions":43,"overallOfficials":17,"centralContacts":53,"locations":59,"responsibleParty":76,"collaborators":17,"id":78,"slug":17,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":79,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":17,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":103,"whyStopped":17,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Biocells Medical","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"NMSS","Change in non-motor symptoms measured by the Non-Motor Symptoms Scale (NMSS) Range: 0-360 360 indicates the greatest symptom burden, 0 - the least","48",[14],{"measure":15,"description":16,"timeFrame":12},"MDS-UPDRS","Change in motor symptoms measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III - Motor Examination Range: 0-132 Where 132 is the worst motor impairment and 0 is the best",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":24},"DOUBLE",[25,26],"PARTICIPANT","INVESTIGATOR",[28,34,39],{"label":29,"type":30,"description":31,"interventionNames":32},"Neuroinduced Mesenchymal Stem Cells","EXPERIMENTAL","200,000,000 neuroinduced mesenchymal stem cells administered via intravenous infusion.",[33],"Biological: Intrathecal (IT)",{"label":35,"type":30,"description":36,"interventionNames":37},"Mesenchymal Stem Cell Derived Exosomes","1×10¹¹ particles per infusion",[38],"Biological: Intravenous",{"label":40,"type":41,"description":17,"interventionNames":42},"Intravenous saline infusion","PLACEBO_COMPARATOR",[38],[44,49],{"type":45,"name":46,"description":47,"armGroupLabels":48,"otherNames":17},"BIOLOGICAL","Intrathecal (IT)","Intrathecal injection of 3 ml between L4-L5",[29],{"type":45,"name":50,"description":51,"armGroupLabels":52,"otherNames":17},"Intravenous","Intravenous injection via a drip",[40,35],[54],{"name":55,"role":56,"phone":57,"phoneExt":17,"email":58},"Andrei Peskau","CONTACT","+48452365311","info@biocellsmedical.com",[60],{"facility":61,"status":17,"city":62,"state":17,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Neuropostep","Warsaw","02-797","Poland","PL",{"type":67,"coordinates":68},"Point",[69,70],21.01178,52.22977,{"lat":70,"lon":69},[73],{"name":74,"role":56,"phone":75,"phoneExt":17,"email":58},"Anita Gerder","+48223074882",{"type":77,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100629173",false,"NCT07471230","Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism","Phase II Randomized Controlled Trial Evaluating Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism","STEM-PARK","Inclusion Criteria:\n\nAge 40-80 years Clinical diagnosis of Parkinsonism Hoehn and Yahr stage II-III Stable pharmacological treatment for ≥3 months\n\nExclusion Criteria:\n\nAtypical parkinsonian syndromes unrelated to neurodegeneration History of malignancy within 5 years Severe cardiovascular disease Prior cellular therapy Active infection or immunosuppression","ALL","48 Years","70 Years",{"count":89,"type":90},120,"ESTIMATED","INTERVENTIONAL",[93],"PHASE2","This clinical trial investigates the safety and therapeutic potential of mesenchymal stem cell-based therapies in patients with parkinsonism.\n\nThe study evaluates neuroinduced mesenchymal stem cells and mesenchymal stem cell-derived exosomes as potential regenerative treatments targeting neurodegeneration within dopaminergic pathways.",[96,97],"Parkinsonism or Parkinson's Disease Nos","Parkinsonism in Diseases Classified Elsewhere",[99,100,101,102],"mesenchymal","exosomes","parkinsonism","stem cells","NOT_YET_RECRUITING","2026-03-10",{"date":106,"type":107},"2026-03-13","ACTUAL",{"date":109,"type":90},"2026-11-23",{"date":111,"type":90},"2029-11-23",{"name":5,"class":6},1]